What triggered the TDOC analyst rating upgrade by BofA?

BofA cited BetterHelp’s shift toward insurance revenue and potential margin upside as the main trigger. The firm sees this structural change as likely to improve revenue quality and boost margins over coming quarters.

What is the new price target after the TDOC upgrade?

Bank of America set a **$7** price target with the upgrade. Price targets reflect analyst assumptions about revenue and margin trends and should be weighed against current share price and company fundamentals.

How should investors interpret the TDOC upgrade versus stock moves?

An upgrade signals more positive analyst expectations, but the stock can still move lower short term. Compare the **$7** target, the **-14.5%** recent move, and Teladoc’s financials before deciding.

How does Meyka AI factor the TDOC analyst rating into its grade?

Meyka AI rates TDOC **B+** by combining S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is a composite signal and not investment advice.

Analyst Ratings

BofA Securities Upgrades Teladoc Health, Inc. (TDOC) to Buy Feb 26, 2026

ByDanny Kontos February 27, 2026February 27, 2026

Bank of America Securities upgraded Teladoc Health, Inc. (TDOC) from Neutral to Buy on February 26, 2026. The TDOC analyst rating change points to BetterHelp shifting toward insurance contracts and near-term margin upside. BofA set a $7 price target and flagged recent share moves of -14.5% and -$0.77 since the prior note. Meyka AI data shows a market cap of $953,688,836 and tracks analyst shifts in real time. We summarize the upgrade, its investor implications, and where Teladoc stands in analyst coverage.